Past experience and future studies with antilymphocyte globulin in recipients of kidney homografts.
We remain convinced that antilymphocyte globulin (ALG) is a potent immunosuppressive agent in humans. For that reason, we have used it in essentially every case of renal transplantation since May of 1966; now, however, we are about to embark on a controlled clinical  trial of ALG in kidney transplantation and await with tremendous interest the results of other such trials from other centres around the world.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation; D013997:Time Factors; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum